Organisation mondiale de la Santé. Bureau régional de la Méditerranée orientale (Publication Date: 2026-09-15)
No dc.description.abstract in the captured record.
not held here
The primary objective of the Institutional Repository for Information Sharing (IRIS) is to provide free digital access to the scientific and technical publications of the World Health Organization (WHO), including contributions from its Country Offices, Regional Offices, and Headquarters. Additionally, IRIS encompasses the mandates established by the Organization’s Governing Bodies in collaboration with its Member States.
Replica. No WHO emblem, no photograph — colour only, from the iris-web theme measured off the site’s own stylesheet.
Search across 12 items held by value and referenced communities/collections. To look up any of the 223 referenced nodes by identifier, search here or open the identifier lookup. Upstream IRIS reports 273,559 items across 1,057,223 files.
Ordered by dc.date.accessioned, latest first — the key IRIS’s own list sorts on. Where a record carries several accessions the latest is used; the WPRO item has two, five days apart, the second being the regional-IRIS merge.
Organisation mondiale de la Santé. Bureau régional de la Méditerranée orientale (Publication Date: 2026-09-15)
No dc.description.abstract in the captured record.
not held here
World Health Organization (Publication Date: 2026-07-22)
HIV remains a major public health challenge, particularly in low- and middle-income countries, despite the availability of effective treatment and prevention tools. Many evidence-based interventions are not implemented consistently or delivered in a timely manner, contributing to ongoing HIV transmission, advanced disease and preventable mortality. These consolidated WHO guidelines provide evidence-based recommendations to strengthen HIV service delivery through people-centred, integrated and equitable approaches that improve access to care, continuity of treatment and accelerate progress towards ending AIDS as a public health threat. The publication consolidates all WHO recommendations on HIV service delivery issued between 2013 and 2025. It is intended to support the development of national and subnational policies, clinical guidelines and implementation guidance. It addresses key components of HIV service delivery, including linkage to care and antiretroviral therapy initiation, clinical follow-up and medication refills, adherence support and re-engagement in care, services for adolescents and young people, task sharing, decentralized service delivery, and integration with maternal and child health, tuberculosis, sexual and reproductive health, diabetes, hypertension and mental health services. Recommendations are classified as new, updated or revalidated according to WHO guideline development procedures.
not held here
World Health Organization (Publication Date: 2026-06-22)
This report presents the 2026 edition of the National Health Workforce Accounts (NHWA) series, providing an overview of the status of NHWA implementation and an analysis of global and regional health workforce levels and trends based on official data reported by countries to the World Health Organization. Developed to support evidence-informed health workforce policy-making and planning, the report examines progress in strengthening national health workforce information systems, data availability and reporting across countries, and the use of standardized indicators to monitor human resources for health in support of universal health coverage, the Sustainable Development Goals and other health objectives. Drawing on the 2025 NHWA data release, the report analyses the distribution, density and composition of the health and care workforce across regions and income groups, highlighting persistent disparities in workforce availability. It also examines trends in workforce growth since 2006 and presents a thematic analysis of population ageing and health workforce ageing, assessing their implications for future workforce needs. The findings demonstrate substantial improvements in the availability and quality of health workforce data through NHWA implementation while underscoring continuing challenges related to workforce shortages, inequities in distribution and the need for sustained investment in health workforce planning and monitoring.
9789240122925-eng.pdf · via CDN · 3.58 MB
World Health Organization (Publication Date: 2026-06-09)
This handbook provides practical guidance to support countries in planning, designing and implementing digital solutions for reporting substandard and falsified medical products. These products pose a significant threat to public health, contributing to therapeutic failure, adverse effects, loss of trust in health systems and broader socioeconomic impacts. Effective detection and reporting are essential to enable regulatory authorities to investigate suspected cases, remove harmful products from circulation and contribute to global surveillance efforts through mechanisms such as WHO’s Global Surveillance and Monitoring System. The document outlines a structured approach to digital transformation, covering assessment of the current environment, stakeholder engagement, governance and policy alignment, definition of system requirements, implementation planning, and monitoring and evaluation. It emphasizes the transition from fragmented or paper-based reporting systems to interoperable digital platforms that improve data quality, standardization and timeliness. Drawing on global experience and existing WHO frameworks, the handbook promotes the use of user-centred design, open standards and integration with pharmacovigilance systems. It is intended for ministries of health, national regulatory authorities and partners seeking to strengthen reporting systems and enhance the capacity to detect and respond to substandard and falsified medical products.
not held here
World Health Organization (Publication Date: 2026-04-24)
This report provides a comprehensive assessment of the global burden of viral hepatitis and progress towards the goal of eliminating hepatitis as a public health threat by 2030. Drawing on data reported by Member States and modelled estimates, it analyses trends in incidence, prevalence and mortality associated with hepatitis B and C, covering the period from 2015 to 2024 based on the latest available data. It also situates these trends within the context of global commitments, strategies and targets. The publication reviews the coverage and impact of key interventions for prevention, diagnosis and treatment, including vaccination, infection prevention and control, harm reduction and access to antiviral therapies. It identifies persistent gaps in testing and treatment, marked regional disparities, and the need for accelerated scale-up of services, particularly in high-burden settings. The report concludes that progress towards the 2030 elimination targets remains off track despite the availability of effective interventions. Intended for policymakers, programme managers and public health stakeholders, it serves as an analytical and strategic resource to guide national and global responses to viral hepatitis.
not held here
Khadijeh Ezoji; Mohsen Yaghoubi; Marzieh Nojomi; Sussan Mahmoody; Seyed Mohsen Zahraie; Maziar Moradi-Lakeh; Sedigheh R. Tabatabaei; Abdollah Karimi (Publication Date: 2019-10-29)
Background: Pneumococcal disease caused by Streptococcus pneumoniae results in considerable mortality and morbidity. Pneumococcal conjugate vaccines (PCV), such as PCV-13, can prevent invasive pneumococcal disease and avoid disability and death. The cost of introducing PCV-13 in childhood immunization schedules should be assessed against the cost of pneumococcal diseases for each community. Aims: This study aimed to evaluate the cost–effectiveness of introducing PCV-13 in the national immunization programme for children under 5 years in the Islamic Republic of Iran. Methods: The TRIVAC decision support model was used to estimate total costs of introducing PCV-13 and the disability-adjusted life years (DALYs)averted. The main pneumococcal diseases were considered—pneumonia, meningitis, acute otitis media, and non-pneumonia, non-meningitis infections—in terms of hospital admissions, outpatient visits and deaths. Local data were used to estimate costs. Results: Pneumococcal disease is estimated to affect 18 713 211 children under 5 years (519 412 pneumonia, 18 148 116 acute otitis media, 6884 meningitis, and 38 799 non-pneumonia, non-meningitis)in 10 years (2014–2023)without use of the vaccine. Introduction of PCV-13 would prevent 4 900 084 cases of pneumococcal disease (190 849 pneumonia, 4 692 450 acute otitis media, 2529 meningitis, and 14 256 non-pneumonia, non-meningitis). Pneumococcal infection would cause 287 950 hospital admissions and 29 399 deaths; vaccination could avert 105 802 hospital admissions and 9997 deaths. The incremental cost–effectiveness was estimated to be US$ 1890 and US$ 1538 per averted DALY for the government and society respectively. Conclusion: According to WHO-recommended thresholds for interpreting cost–effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective
not held here
World Health Organization (Publication Date: 2025-10-30)
This handbook provides guidance for the implementation of standardized product master data management through national product catalogues (NPCs) to support digital transformation in health supply chains. Developed within the framework of the WHO Digital Implementation Investment Guide and aligned with the SMART Guidelines initiative, the publication outlines regulatory, governance, technological and operational approaches for establishing interoperable product registries and harmonized product information systems. It explains the importance of standardized product master data for ensuring accurate identification, tracking and management of health products across manufacturers, regulatory authorities, procurement entities, warehouses, health facilities and other supply chain stakeholders. The handbook describes policies and procedures for data governance, coding structures, interoperability standards, change management and capacity-building to support sustainable implementation. It also presents guidance on integrating standardized product master data with digital health, regulatory and supply chain systems to improve forecasting, procurement, inventory management, pharmacovigilance, product recalls and traceability. In addition, the publication highlights mechanisms for sharing product master data as a global good and leveraging WHO-hosted tools and open standards to strengthen coordination, data quality and supply chain efficiency across countries and organizations.
9789240116191-eng.pdf · via CDN · 1.30 MB
World Health Organization (Publication Date: 2025-04-10)
This web annex to the WHO consolidated guidelines on tuberculosis, Module 3: Diagnosis, compiles the evidence synthesis and analyses used to inform WHO recommendations on diagnostic technologies for tuberculosis and drug-resistant tuberculosis. The publication presents systematic reviews, meta-analyses, qualitative evidence syntheses and economic evaluations examining the diagnostic accuracy, safety, cost–effectiveness and implementation considerations of multiple diagnostic approaches, including low- and moderate-complexity nucleic acid amplification tests, targeted next-generation sequencing technologies and Mycobacterium tuberculosis antigen-based skin tests. The annex describes the methods applied to identify, assess and synthesize evidence across diverse populations and settings, including adults, adolescents, children and people living with HIV. It addresses the detection of pulmonary and extrapulmonary tuberculosis, rifampicin resistance and multidrug-resistant tuberculosis using respiratory and non-respiratory specimens. The document also examines stakeholder and user perspectives, operational feasibility and factors influencing implementation. Developed in accordance with WHO guideline development standards, the annex provides the technical evidence base underpinning updates to WHO policy guidance on tuberculosis diagnosis and drug-resistance testing.
not held here
World Health Organization (Publication Date: 2024-12-31)
This publication presents the World Health Organization’s digital adaptation kit (DAK) for immunizations, developed within the SMART Guidelines framework to support the implementation of WHO immunization recommendations in digital systems. The document provides operational and software-neutral specifications intended to facilitate the translation of immunization guidance into interoperable digital health applications, particularly person-centred point-of-service systems and electronic immunization registries. It outlines the role of digital adaptation kits in strengthening digital health systems by improving the consistency, transparency and standardization of health content, workflows, data structures and decision-support logic used in immunization programmes. The publication also situates the DAK within broader digital health strategies and interoperability standards. The document describes eight core components of the immunization DAK, including health interventions and recommendations, generic personas, user scenarios, workflows, core data elements, decision-support logic, indicators and functional requirements. It incorporates WHO guidance related to routine immunization, electronic immunization registries and digital health interventions, while emphasizing adaptability to country-specific policies and implementation contexts. Additional sections address interoperability, data standards, workflow optimization and the use of digital systems to support longitudinal tracking, reporting, decision support and communication within immunization services. The publication is intended for immunization programme managers, digital health teams, software developers and implementers involved in designing and deploying digital immunization systems.
not held here
World Health Organization (Publication Date: 2024-11-11)
This handbook provides practical guidance for countries seeking to digitally transform public health supply chains through the development of coherent strategies, interoperable architectures and sustainable implementation approaches. Developed within the WHO SMART Guidelines framework, it addresses the growing need for integrated digital ecosystems that support forecasting, procurement, warehousing, distribution, dispensing and traceability of health products. The publication outlines the role of digital technologies in improving efficiency, data availability, interoperability and decision-making across supply chain processes, while helping ensure timely access to quality-assured medicines and health products. The publication presents a stepwise approach for defining a digital health supply chain (DHSC) strategy, assessing existing health supply chain information systems, designing a target architecture, planning implementation and supporting product traceability. It emphasizes stakeholder engagement, alignment with national health, digital health and supply chain strategies, use of open standards, and long-term scalability and sustainability. Drawing on country experiences and established digital health frameworks, the handbook offers practical tools, templates and examples to support governance, planning and coordination of digital transformation initiatives, with the aim of strengthening supply chain performance, improving visibility across the supply chain and enhancing patient safety.
9789240101197-eng.pdf · via CDN · 2.01 MB
iris.who.int/community-list, with every node’s materialisation state (9 communities, 4 collections)